Adage Capital Partners’s Xilio Therapeutics XLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.2M Buy
464,598
+353,057
+317% +$3.2M 0.01% 854
2026
Q2
$1.07M Buy
+111,541
New +$932K ﹤0.01% 895

Other funds holding XLO

Adage Capital Partners's XLO Position: Q3 2026 in Review

Adage Capital Partners increased its Xilio Therapeutics (XLO) stake by 317% in Q3 2026, buying an estimated $3.2M and bringing the position to 464,598 shares worth $4.2M. The position accounts for 0.01% of the portfolio, ranked #854.

Adage Capital Partners first reported a position in XLO in Q2 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

  • Adage Capital Partners held 464,598 shares of Xilio Therapeutics worth $4.2M as of Q3 2026.
  • Adage Capital Partners bought 353,057 Xilio Therapeutics shares in Q3 2026, an estimated $3.2M.
  • Xilio Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q3 2026, its #854 holding.
  • Adage Capital Partners first reported a position in Xilio Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.